Investigational Drug Information for Adavosertib
✉ Email this page to a colleague
What is the development status for investigational drug Adavosertib?
Adavosertib is an investigational drug.
There have been 29 clinical trials for Adavosertib.
The most recent clinical trial was a Phase 1 trial, which was initiated on December 31st 2013.
The most common disease conditions in clinical trials are Neoplasms, Carcinoma, and Adenocarcinoma. The leading clinical trial sponsors are National Cancer Institute (NCI), AstraZeneca, and Parexel.
Summary for Adavosertib
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 159 |
| WIPO Patent Applications | 145 |
| Japanese Patent Applications | 15 |
| Clinical Trial Progress | Phase 1 (2013-12-31) |
| Vendors | 63 |
Recent Clinical Trials for Adavosertib
| Title | Sponsor | Phase |
|---|---|---|
| Adavosertib and Gemcitabine in Advanced Pancreatic | AstraZeneca | Phase 2 |
| Adavosertib and Gemcitabine in Advanced Pancreatic | Lustgarten Foundation | Phase 2 |
| Adavosertib and Gemcitabine in Advanced Pancreatic | Stand Up To Cancer | Phase 2 |
Clinical Trial Summary for Adavosertib
Top disease conditions for Adavosertib
Top clinical trial sponsors for Adavosertib
US Patents for Adavosertib
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
